Weight loss as new diabetes target could boost sales of Novo Nordisk's obesity drug

Wallets at Novo Nordisk might get fatter if enduring weight loss becomes the primary treatment goal for people with type 2 diabetes, as several researchers have proposed in the Lancet, Danish business daily Børsen reports on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
Novo Nordisk starts crucial trial of obesity tablet
For subscribers